Rapid market acceptance and ease of use have helped thin film revenue skyrocket
Los Angeles, CA (PRWEB) November 28, 2012
The Thin Film Drug Manufacturing industry has experienced rapid growth due to its touted advantages over more traditional drug delivery systems (e.g. pills and liquids) and increasing consumer acceptance of the product. Over the five years to 2012, IBISWorld expects industry revenue to grow at an annualized rate of 30.9% to about $1.0 billion. This dramatic growth is indicative of both increasing demand for thin film drugs as well as the technology's relative immaturity; thin film drug delivery was first introduced less than a decade ago in 2004. While the majority of thin film drugs are over-the-counter (OTC) drugs (i.e. drugs that can be purchased without a prescription), an increasing number of thin film prescription drugs will likely be brought to market as the delivery technology matures and major branded drugs lose patent protection. Revenue is expected to grow 10.2% in 2012 as an increasing number of thin film drugs are brought to market.
Thin film drugs dissolve more quickly than pills and can be ingested without water, making them ideal for pediatric patients, patients with swallowing disorders or patients with nausea or vomiting. Additionally, industry participants have touted thin film drugs' improved dosing efficiency. These drugs contain an exact dose of a drug and are not subject to degradation from digestive enzymes; consequently, the drugs can contain smaller, more accurate doses than their pill or liquid counterparts and achieve the same effect in less time. These advantages over other drug delivery systems have been the driving force behind the industry's growth over the past five years. The Thin Film Drug Manufacturing industry exhibits a high level of industry competition. The top three companies are Novartis AG, Reckitt Benckiser PLC and Pfizer Inc. These multinational firms produce a wide range of medicinal products, allowing them to potentially cut down on per-unit product costs and spend more in terms of research and development (R&D). In addition, these companies have capitalized on previous brand name products to gain a strong position in the thin film drug industry. Some firms have established much smaller positions through selling less commonly demanded products. For example, Par Pharmaceutical distributes Zuplenz in a thin film format. Zuplenz works to reduce nausea and other post-chemotherapy side effects; however, revenue is estimated to be around only $1.0 million. IBISWorld estimates that market share concentration will decline slightly during the next five years as major pharmaceutical competitors make their way into the growing industry.
Over the next five years, industry revenue is forecast to grow. As the number of individuals eligible for Medicare and with private insurance plans increases, industry firms will seek to leverage the thin film drug delivery's advantages over other drug delivery systems in order to have their drugs covered under insurance plans. Additionally, the industry's scope is expected to increase as an rising number of thin film prescription drugs are brought to market. As brand name pharmaceutical manufacturers lose patent protection on their drugs, they may seek to offer a thin film version of their product to maintain a competitive advantage over generic versions. Similarly, generic drug manufacturers may seek to offer a thin film version of their drug to differentiate themselves in a highly competitive market. For more information, visit IBISWorld’s Thin Film Drug Manufacturing in the US industry report page.
Follow IBISWorld on Twitter: https://twitter.com/#!/IBISWorld
Friend IBISWorld on Facebook: http://www.facebook.com/pages/IBISWorld/121347533189
IBISWorld industry Report Key Topics
This industry manufactures dissolving films or oral drug strips that are used to administer drugs via absorption in the mouth or via the small intestines. Thin film use has emerged as an advanced drug delivery method that makes drugs easy to swallow without water and improves dosing accuracy. Additionally, offering a drug in thin film form can extend product life cycles for pharmaceutical companies that have expiring drug patents and may be exposed to generic competition.
Key External Drivers
Industry Life Cycle
Products & Markets
Products & Services
Globalization & Trade
Market Share Concentration
Key Success Factors
Cost Structure Benchmarks
Barriers to Entry
About IBISWorld Inc.
Recognized as the nation’s most trusted independent source of industry and market research, IBISWorld offers a comprehensive database of unique information and analysis on every US industry. With an extensive online portfolio, valued for its depth and scope, the company equips clients with the insight necessary to make better business decisions. Headquartered in Los Angeles, IBISWorld serves a range of business, professional service and government organizations through more than 10 locations worldwide. For more information, visit http://www.ibisworld.com or call 1-800-330-3772.